CASP3 and breast carcinoma: Previously we observed that co-treatment of DET with JNK inhibitor SP600125 notably reduced DET induced p21WAF1/Cip1 and cleaved forms of PARP and caspase-3 in TS/A cells [8], indicating that DET acts differentially on the JNK activation and JNK-mediated signaling in different breast cancer cell types.